Rankings · Price against the business
A-graded, furthest below their high
Graded A, ranked by how far the share price sits below its 52-week high. The grade is built from the filings alone; the fall is a fact about the price, not the business.
68 companies meet this test
Figures as of November 15, 2026
| # | Company | Grade | Below 52-week high | P/E | Market value |
|---|---|---|---|---|---|
| 1 | VCYTVERACYTE, INC. | A+ | -60% | 15.80 | $2B |
| 2 | NRIXNURIX THERAPEUTICS, INC. | A+ | -44% | 6.73 | $1.7B |
| 3 | CORTCORCEPT THERAPEUTICS INC | A+ | -41% | 57.43 | $8B |
| 4 | LQDALIQUIDIA CORPORATION | A | -37% | — | $5.2B |
| 5 | CAICARIS LIFE SCIENCES, INC. | A | -36% | 13.88 | $6.6B |
| 6 | BLLNBillionToOne, Inc. | A | -30% | 114.29 | $5B |
| 7 | ILMNIllumina, Inc. | A+ | -30% | 35.63 | $31.3B |
| 8 | ISRGIntuitive Surgical, Inc. | A+ | -25% | 53.70 | $153.8B |
| 9 | HALOHALOZYME THERAPEUTICS, INC. | A+ | -24% | 25.01 | $11.4B |
| 10 | INNVInnovAge Holding Corp. | A | -22% | 157.83 | $1.3B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.